Abstract
Introduction

New approaches to clinical problems based on translational medicine start with basic research and progress 'hand-in-hand' with clinical observations. Scientists are increasingly aware that this 'bench-to-bedside' approach to translational research is really a two-way street which can strengthen and accelerate critical points of the research process. Bone defects due to trauma and to pathological and physiological bone resorption represent a major challenge and are a global health problem. The need for bone regeneration in cranial, oral and maxillo-facial and orthopaedic surgery is one of the central clinical issues in regenerative and rehabilitation medicine. It is difficult to convey the enormous social and psychological handicap of persons with bone defects and the significant reduction in their quality of life. In addition to trauma, bone healing problems may be related to age, sex and infection as exemplified by diagnoses such as osteoporosis, osteopenia and severe dental problems related to loss of teeth. The aim of this review is to describe the current state of the art in our understanding of bone healing and bone regeneration.
Bone fracture healing and healing problems
Bone repair after fracture is a special process where sequential cellular and molecular events take place to generate new bone, rather than a fibrous scar like other connective tissues. The precise series of ordered events required to produce new bone are modulated by systemic and local factors, and disruption of these orderly events may cause healing problems. Thus, a clear understanding of the sequence of events and their regulation is needed to decide when and how an intervention is required to promote healing and to avoid complications.
Since early histological descriptions of fracture healing in man [1] , the general pattern of indirect fracture healing, based on endochondral ossification, has included the chronological phases of haematoma, inflammation, angiogenesis, chondrogenesis to osteogenesis and finally bone remodelling [2] . [5] . Finally, angiogenesis, a key aspect of fracture healing, is also regulated at the molecular level. An angiopoietin pathway has been described in the early stages of the healing process [6] , as has a vascular endothelial growth factor (VEGF)-dependent pathway related to endochondral bone formation, where BMPs stimulate the expression of VEGF by osteoblasts and osteoblast-like cells [7] . Inhibitory molecules are also needed to control growth factors (GFs) , and various BMP antagonists [8] are released into the extracellular compartment (noggin, sclerostatin, follistatin, etc [9] , and intracellular inhibition by the activation of I-Smads [10, 11] [13, 14] . Mechanical influences on biological processes, known as mechanobiology, significantly affect all phases of bone formation. Not only may major external forces disrupt the healing process, but mechanical loading influences on endochondral ossification are also important as compression enhances bone apposition [13] , empirically defined since the 19th century as Wolff ' [15, 16] , to fluid shear stresses and various matrix effects that indirectly affect cells [17] . Many of these experimental studies were developed after clinical studies showed the beneficial influence of interfragmentary motion (of about 0.6 mm) in the early stages of the healing process [18] , and the role of mechanical stimulus in general as an influence on the rate of healing.
Direct healing based on membranous ossification, with no periosteal reaction or visible callus formation, is seldom seen. The well-established characteristics of the above mentioned phases require different processes of cell migration and differentiation, extracellular matrix formation and organization towards calcification, as well as both local and systemic modulation. Apart from the classical histological phases of fracture healing, much remains to be understood about the regulation of these processes both at the molecular and the cellular level. Formation of a haematoma related to blood vessel damage is accompanied by an inflammatory response [3], where proinflammatory cytokines such as interleukin-1 (IL-1), IL-6, and particularly tumour necrosis factor-␣, initiate the bone healing cascade and push it towards endochondral bone formation and remodelling [4]. Secondarily, apart from ischemia, growth and differentiation factors and particularly the transforming growth factor-␤ (TGF-␤) superfamily, including bone morphogenetic protein (BMPs), as well as platelet-derived growth factors (PDGF), fibroblast growth factors (FGFs) and insulin-like growth factors (IGFs), orchestrate crucial events for chondro-osteogenesis, including chemotaxis, mesenchymal and osteoprogenitor cell proliferation and differentiation, and extracellular matrix ossification
.). Other inhibitory mechanisms include receptor inhibition of some members of the TGF-␤ superfamily that has been related to a pseudo-receptor defined as BAMBI (BMP and activin membrane bound inhibitor)
s law. However, earlier phases of osteogenesis show increased cell proliferation if cyclic motion with associated shear stresses occurs, although intramembranous ossification may be permitted in areas with low stress and strain. Mechanical signalling at the cellular level may modulate molecular changes in cytoskeleton, integrins and ion channel activities with consequences to the differentiation and gene expression of cells involved in the healing process. Transduction mechanisms range from direct mechanical stimulation of cells
Despite this well developed natural mechanism of fracture healing, alteration of local and systemic factors may lead to impaired healing. Non-union (or (Fig. 1) .
The positive results of studies using these systems might be attributable to structural similarity to the mineral phase of bone, and osteoconductive and bone-binding properties [43] [44] [45] [53] . Another interesting system is copolymerization with dioxanone. Poly (1,5-dioxepan-2-one) (Fig. 3) is an amorphous polymer: the soft, amorphous phase provides elasticity and desirable degradation characteristics, whereas copolymerization with lactide gives a rigid crystalline phase, which acts as a physical cross-linker and therefore improves the mechanical properties. It has also been shown that the hydrophilicity of the polymer changes when different monomer compositions are used [54, 55] . In a series of experiments using poly (1,5- [61, 62] . During bone formation phase, the osteoblasts are recruited from MSC present in bone marrow [63] . On the other hand, osteoclasts are derived from haematopoietic stem cells through committed osteoclast progenitors that fuse to form mature multinucleated cells [64] . [77] , CD271 (low-affinity nerve GF receptor) [78] , CD18 (␤2 integrin) [79] or the embryonic stem cell marker SSEA-4 [80] have been tried. A global plasma membrane proteomic signature has been established in order to identify novel surface markers for 'stemness' [75] . However, there is still a need to identify both sensitive and specific markers that allow prospective isolation of the true multipotent MSC population.
Mesenchymal stem cells and osteogenesis
Bone tissue
Bone tissue is composed of bone matrix and bone cells. Bone matrix is primarily built of type I collagen (90%), with the remaining 10% being composed of a large number of non-collagenous proteins (e.g. osteocalcin [OC], osteonectin, bone sialoproteins and various proteoglycans). Non-collagenous proteins participate in the process of matrix maturation, mineralization and may regulate the functional activity of bone cells. Two main types of bone cells have been identified. Osteoblasts (bone-forming cells) and osteoclasts (bone resorbing cells) that together with their precursor cells and associated cells (e.g. endothelial cells, nerve cells) are organized in specialized units called bone multicellular units (analogous to the organization of kidney cells into nephrons) [61]. The main function of the bone multicellular units in the adult skeleton is to mediate a bone 'rejuvenation' mechanism called 'bone remodelling' aimed at the maintenance of the integrity of the skeleton by removing old bone of high mineral density and high prevalence of fatigue micro-fractures through repetitive cycles of bone resorption and bone formation
Understanding the mechanisms that control the differentiation of osteoblastic cells from MSC is thus of one of the fundamental areas of research of bone biology. The ability of MSC to differentiate into non-osteoblastic cells has been recognized recently and here we attempt to provide an update regarding the trans-differentiation potential of MSC with regard to the relationship between osteoblast and adipocyte differentiation.
Origin of osteoblasts
Interestingly, MSC with similar biological characteristics to those derived from bone marrow have been isolated from other sources including peripheral blood [81] , umbilical cord blood [82] , synovial membrane [83] , deciduous teeth [84] and amniotic fluid [85] . These various MSC populations share some common properties and surface phenotypes but differ in their differentiation potential and their gene expression profile in ways that reflect their tissue of origin [86] . [71, 88, 89] . [66] . Ectopic [87, 90, 91] . Under these conditions, MSC can form bone and a bone marrow microenvironment supporting haematopoesis, whereas osteoprogenitor cells can only form bone [91] . This assay has also been employed to demonstrate the ability of the multipotential MSC cell to exhibit self-renewal and maintenance of stemness capacity during serial implantations [92] .
In vitro differentiation of MSC into osteoblast lineage cells
In vivo differentiation of MSC into bone
There is increasing recognition that in vitro osteoblast differentiation assays have limitations and thus there is a need to verify osteoblast differentiation potential of MSC based on an in vivo assay. Friedenstein employed 'diffusion chambers' to determine the differentiation potential of MSC
The importance of testing the in vivo phenotype of cultured MSC is shown by the recent demonstration of the limited value of standard in vitro criteria for identification of hMSC clones with in vivo bone-forming capacity [93] . In this study, using DNA microarray analysis, a predictive molecular signature was identified for in vivo bone formation of MSC that can be employed to select for an MSC population with high in vivo osteogenic capacity for bone regeneration [93] . [94] , osterix [95] (Osx) and lipoprotein related receptor 5 (Lrp5) [96] overexpression lead to osteoblast differentiation, whereas PPAR-␥2 [97] and Sox9 [98] [99] , Wnt [100] or that inhibit osteoblast differentiation, e.g. Dlk1/Pref-1 [101] and Noggin [102] .
Factors and pathways controlling osteoblast differentiation of hMSC
We have employed novel proteomic approaches to identify the intracellular signalling pathways that determine the osteoblast differentiation fate of MSC [103] 
Defining the relationship between osteoblast and adipocyte differentiation from MSC
Recent studies have suggested that bone mass and fat mass are strongly associated processes mediated by the same hormonal factors, including insulin [104] , growth hormone [105] and recently leptin [106] . [109] , PPAR-␥2 [110] , ⌬FosB [111] , canonical Wnt-␤-catenin and non-canonical Wnt signalling pathways [112] . We have also reported that Wnt co-receptor, Lrp5 with active mutation (T253I) and Wnt activation control the differentiation of hMSC into osteoblast versus adipocyte in patients with high bone mass due to this mutation [96] .
On the other hand, bone marrow adipocytes secret several inflammatory factors, including leptin, adipsin, adiponectin and resistin, that act in a paracrine manner to suppress osteoblast function and differentiation [113, 114] . Very recently, Lee et al. [115] provided the first evidence that bone can act as an endocrine organ to regulate glucose and fat metabolism through the secretion of OC (osteoblast-specific protein), which acts as a prohormone to decrease fat mass and promotes expression of adiponectin, an insulin-sensitizing adipokine [115, 116] 
MSC and sex hormones
Sex hormones, especially oestrogens, have a critical role in development and maintenance of healthy skeleton [119, 120] , but it is clear that sex steroids influence not only mature differentiated bone cells, but also the behaviour of stem and different stage progenitor cells [121] . The phytoestrogen genistein enhances osteogenesis and represses adipogenic differentiation of hMSCs [122] .
hMSC express oestrogen receptor (ER)-␣ and possibly also several ER-␤ isoforms [122] [123] [124] [125] [125] .
17␤-estradiol enhances dose dependent osteogenesis from hMSC as shown by up-regulation of OC and increased calcium deposition [124] . In other work, where MSC from both male and female donors were stimulated with estradiol and testosterone, estradiol also increased calcium deposition, but alkaline phosphatase (ALP) activity increased only in cells isolated from male donors [125] . Testosterone, on the other hand, had no effect on calcium deposition in either sex. Resveratrol, a polyphenolic phytoestrogen, has been shown to enhance osteoblastic maturation of hMSC, possibly through extracellular signal-regulated kinase 1/2 (ERK1/2) pathway [126, 127] .
More recent studies have revealed that hMSC can express several key enzymes needed for intracrine conversion of dehydroepiandrosterone to oestrogens or testosterone [122, 128, 129] . This suggests the interesting possibility that hMSC may themselves in certain conditions make the needed sex hormones or adjust their levels using serum dehydroepiandrosterone as a precursor, and participate therefore in an intra-, auto-or paracrine manner in their own differentiation processes and in overall more complex local sex hormone regulation in bone [130] . [135] . The telomerized hMSC exhibit enhanced cell proliferation and in vivo bone formation capacity [135] . Telomerization also enhances gene expression of some osteoblastic genes [136] . Other [137] [138] [139] [140] [141] [142] [143] . Some cell choices are more adaptable to cellular therapy in patients [144] . Tissue from animals and human beings at all stages of development must be evaluated for the advantages and disadvantages of each cell type (Fig. 4) [145] . Cell lines are normally developed from the genital ridge of the foetus but specific tissues can be isolated from immature tissue with the necessity to add GFs to assure particular cellular differentiation. Most foetal cell research has developed from research using specific tissues at the latter end of the first trimester (11) (12) (13) (14) [142, [146] [147] [148] .
Effect of aging on osteoblastogenesis
weeks) following voluntary interruption of pregnancies. As this tissue (Ͼ9 weeks) is considered an organ donation in most countries, it bypasses the major problems that have been raised by embryonic stem cells. Cell lines at this stage are tissue specific and therefore cells are differentiated and have specific functions
Cell-based therapies for bone
The first cell-based strategy used for repair of bone tissue was autologous connective tissue progenitors harvested from the iliac crest and immediately transplanted to sites for skeletal repair in the same patient [149, 150] [138] . [155] . [157] . Spontaneous [161, 165, 166] . Key elements for cellular-based products include identity, purity, sterility, stability, safety and efficacy are recommended. In all, these new regulations impose strict criteria for the production and the environment used for the production of cell-based products to be used in clinical trials and treatments [167, 168] . [32] 
Unlike stem cells, foetal cells are differentiated cells with high expansion and regeneration and low immunogenic properties [154]. They can be isolated from foetal tissues, which follow embryonic stage after 9 weeks of development. Foetal cells have extensive expansion capabilities and cell culture requirements are minimal compared to stem or mesenchymal cell types. As the foetal cells are already differentiated and do not need to be directed or altered, the vast number of additional GFs normally necessary are not needed for cell culture and expansion [146]. Cell choice is of utmost importance and each element of processing necessitates special attention in order to produce a safe, consistent and successful cell therapy for clinical trials
Specific features of bone cells needed to be advantageous for clinical use
As whole bone marrow transplantation may not be optimal biologically, the expansion of bone marrow osteoprogenitors has been evaluated. The procedure is laborious as their isolation and characterization has been difficult due to their low numbers in the original tissue and lack of specific reactive antibodies to assure separation of active cellular components. Patient treatment is only possible following 4-6 weeks of expansion in cell culture. Demonstration of cell function is of particular importance so that separated cells are shown to be capable of matrix deposition, mineralization, ossification, nodule formation and bone formation in vivo without fibrous tissue formation. Although these cells have been shown to fulfil the required needs, it is labour intensive to use these procedures for each individual patient. More recently, femurs from foetal tissue of ~8 weeks were evaluated for isolation of bone progenitors and thus these cell populations would be formally considered as foetal stem cells (5-8 weeks) [156]. Mirmalek-Sani et al. have shown that these cells histologically resemble cartilage and this was confirmed by the high plasticity seen with these cells when compared to studies using foetal bone cell populations derived from 12-to 14 week gestation femurs. In vivo mineralization of 8 week stem cells is seen with osteoinductive media but with 12-14 week foetal bone cells such media are not necessary because spontaneous minerialization is seen without external GFs
Development of therapeutic biological agents
Organ donation, whole cell bioprocessing and procedures adaptable to good manufacturing processes (GMP) make it possible to develop extensive master cell banks and working cell banks to facilitate thorough testing (Fig. 5) [159]. Once master cell banks can be produced, working cell banks can be produced to establish individual batches for treatment of large numbers patients (thousands from one cell bank). Further, these cell banks can be tested completely for safety regarding sterility, pathogens and adventitious agents and tumorigenicity. Once safety can be assured, efficient cell presentation with biocompatible delivery systems can be assessed for specific tissues. For delivery systems, biocompatible biomaterials need to be available in order to provide an extracellular matrix environment for cell differentiation, delivery and release. Cells and materials need to be tested together to not only assure biocompatibility but also their interactions, cellular stability, possible degraded by-products of combination and degradation or absorption. Ease of applicability of the final product will be of importance for clinical use. All cellular products must be in compliance with GMP guidelines with respect to medicinal products and investigational medicinal products for human use. The European Union (EU) regulation on advanced therapy medicinal products was adopted by all European Member States on December 30, 2008 and the United States Food and Drug Administration (FDA) recently also proposed regulations on human cells, tissues and cellular and tissue-based products [160-164]. The main scope of these regulations is to establish clear classification criteria for many new cell-based medicinal products. For the EU, it makes reference to the 2004/23/EC directive on donation, procurement and testing of human cells and tissues and also with directive 2002/98/EC on human blood and blood components. These directives dictate that human cells used for therapeutic purposes must be in compliance with the quality requirements they describe and that all advanced therapy medicinal products must be prepared under GMP conditions
Clinical application concerns
Conclusions
Cell-based therapies are being developed and introduced for all types of tissue repair including skin, bone, cartilage, muscle and
Fig. 5 Organization of a cell therapy platform. Director of technical and logistics coordinates the program with essential legal and ethical advisors and a medical director for interpretation of medical quality assurance (serology and pathology reports). The separation of hospitals for the organ donation and all other aspects of the platform including serology, pathology and the GLP cell culture laboratory can assure complete anonymous and coded organ donations. Importantly, the Director of Technical and Logistics is not involved in any manner in the organ donation process as required by law. Final approval for use of validated cell banks for human therapy is coordinated and approved with both Hospital Ethics Committees and National regulatory agencies (i.e. European Medicines Association, Food and Drug Administration, SwissMedic
Platelet-rich plasma (PRP), growth factors and osteogenesis
PRP is a concentrate of platelets in a small volume of plasma from freshly drawn whole blood activated with a mixture of thrombin and calcium [169] . [170] .
PRP is used to facilitate wound and bone healing, thanks to the molecules released by platelets during activation. A number of these substances affect osteogenesis, such as TGF-␤1, PDGF-BB, VEGF-A and IGF-I (
The combination of GFs in PRP is in an optimal level and ratio, and seems to be more efficient than the single rhGF, owing to their synergistic effects [87] 
. The technique for obtaining GF from PRP is relatively simple and less expensive than rhGF. Because of its autologous origin, PRP does not hold any risk of immunological reactions and transmissible diseases. The drawbacks of PRP are the high variability of GF concentrations, due both to individual factors and to different preparation methods [171]. We found a high variability in PDGF-BB and TGF-␤1 levels assayed in the supernatant of thrombin-activated PRP, on lysates of platelet concentrates, on serum and platelet poor plasma from 11 healthy individuals and from 11 patients with osteonecrosis (Table 2).
The original Marx protocol obtained PRP by the addition of calcium and thrombin to a platelet concentrate [169] . Recently, other protocols for PRP preparation have been proposed, which differ for anticoagulant [172] , leucocyte depletion and platelet activators [173, 174] . Leucocyte depletion avoids the release of pro-inflammatory cytokines [175] . However, some authors suggest that leucocytes represent an additional source of GF and have an important role in host immune defence [176] [177] . [178, 179] and human trabecular osteoblasts [180] . Among the GF released by platelets, the highest contribution to the proliferation of osteoblasts was from PDGF and TGF-␤1 [181] . [183] .
. Myeloperoxidase contained in neutrophils and monocytes generates reactive oxygen species, that act as potent bactericidal and may be helpful to prevent post-surgical infections and in the prophylaxis and treatment of infection-related delayed healing and non-union
PRP effects in vitro on the cells involved in bone repair
PRP effects on osteoblasts The use of PRP was proposed in order to provide a microenvironment for the orchestration of the sequential process of bone regeneration involving migration, proliferation and differentiation of osteogenic cells. The mitogenic effect of PRP was demonstrated by in vitro studies on hMSC
A PRP enriched in fibrin better stimulated proliferation and mineralization of rat osteoblasts than soluble PRP, probably due to a more gradual release of GF from the fibrin component [184] . Additional signals derived from the microenvironment modulate the effects of PRP. hMSC proliferation was increased by the combination of platelet concentrates and demineralized bone matrix, but osteoblastic differentiation decreased [185] . On the contrary, the authors observed that the combination of PRP and freezedried bone allografts accelerated MSC differentiation, as demonstrated by the significantly higher osterix expression at 15 days, and sustained autonomous production of GF by the cells themselves, as shown by the higher level of FGF-2 in the conditioned culture medium after 11 days [186] .
In bone engineering, PRP represents a source of GF to be added to MSC seeded on an artificial scaffold, which could modulate the effects of PRP owing to its physical and chemical properties. PRP favoured the adhesion and proliferation of MSC on three-dimensional ceramic scaffolds with high specific surface area, such as calcium-deficient HA, in comparison with scaffolds with lower specific surface area, such as ␤-TCP [187] . The effect of PRP lysates on the osteogenic differentiation of goat MSC on HA and silica-coated HA was lower than that of fibrin glue, which represents an extracellular matrix with arginine-glycine-aspartic acid motifs that can bind to integrins favouring cell adhesion [188] . However, in clinical use platelet gel preparation generally involves fibrin clotting; therefore platelet gel has the advantages of both platelet concentrates and fibrin mesh. [189] and prostaglandin E2. VEGF favoured osteoclast differentiation in the presence of macrophage colony-stimulating factor [190] .
PRP effects on osteoclasts Activated platelets affect osteoclasts through the release of modulators of osteoclast differentiation, such as TGF-␤1, IGF-I, PDGF
Conflicting results have been reported about the effect of PRP on osteoclasts. In vitro, PRP was shown to favour osteoclast differentiation of mouse bone marrow cells, particularly the generation of tartrate-resistant acid phosphatase (TRACP)
ϩ multinucleated cells, the formation of bone pits and the expression of mRNA for cathepsin K and matrix metalloproteinase-9 [191, 192] . However, other authors found that PRP decreased the generation of TRACP ϩ multinucleated cells from rat bone marrow and enhanced the secretion of osteoprotegerin from osteoblasts [193] . [194] . These results suggest a possible inhibitory effect of the substances released by PRP on osteoclast activation. In vivo, dogs with mandibular defects treated with autologous bone grafts and PRP initially showed an increase of osteoclast number, but after 2 months there was no significant difference between PRP-and non-PRP-added grafts [195] .
On the basis of these results, we suggest that PRP can have opposing effects on osteoclast generation and differentiation through the simultaneous interaction of several released molecules with osteoclast precursors. TGF-␤1 could be a possible inhibitor of terminal differentiation of osteoclasts, because TGF-␤1
has been shown to favour the recruitment of haematopoietic precursors [196] but to inhibit bone resorption [197] .
PRP effects on endothelial cells
Angiogenesis is crucial for good bone healing. Newly formed vessels mediate delivery of cell precursors, secrete GF and transport nutrients and oxygen [198] . Endothelial cells synthesize molecules which affect bone cells, such as cytokines, chemokines, prostanoids, GF, adhesion molecules, matrix constituents [199] , endothelin-1 [200] and BMP-2 [201] . The GF released by platelets, such as VEGF, TGF-␤, PDGF and EGF [202] , not only have pro-angiogenic properties [203] [204] [205] , but also induce the endothelial cells to express a pro-osteogenic phenotype. PRP induced human umbilical endothelial cells (HUVEC) to express PDGF-␤, which in turn has chemotactic effects [206] , recruiting MSC to the site of bone repair. MSC migration was higher in HUVEC incubated with PRP in comparison with HUVEC incubated with low serum medium or with PRP [207] . PRP favours monocyte adhesion to the vessel wall, through the stimulation of endothelial cell expression of intercellular adhesion molecule 1 [207] , which is important because the monocyte/macrophage response is essential for bone repair.
PRP effects in vivo on experimental animals
The results of research on osteogenic activity of PRP in animals are conflicting. In combination with bovine cancellous bone, PRP increased bone formation in a non-critical-size bone defect in rabbit cranium [208] . However, other authors noticed that the use of bone graft material in combination with PRP was not superior to that of bone allograft alone [209] [210] [211] . These different results may depend on the animal species used, the method of gel preparation, type of bone defect, outcome parameters measured, the presence of MSC and of scaffolds or bone substitutes. An important reason for the discordant results from different authors is the fact that critical-size bone defects were not assayed. When critical-size bone defects were tested, the combination of PRP, bone substitutes and MSC induced the greatest improvement in healing compared to a single component assayed alone [212] . Another variable seems to be the ratio of bone graft to PRP [213] .
When PRP was used in combination with artificial scaffolds, the physical and chemical properties of the scaffold material should be considered because they can affect the performance of PRP [187] . When PRP was used in association with ␤-TCP [214] or triphasic ceramic-(calcium silicate, HA and TCP) coated HA [215] , more intense bone regeneration was observed.
Even though it is generally assumed that PRP might support osteogenesis in the presence of precursor cells, sometimes the addition of PRP to MSC did not further increase the rate of bone formation in comparison to MSC alone. In goats no effect was shown when PRP was added to MSC seeded on scaffolds made of the combination of HA and ␤-TCP implanted at an orthotopic or ectopic location [216] . MSC added to the critical size defect were likely already induced towards osteogenesis and PRP could not significantly increase this. Moreover, osteotomy might recruit osteoblast precursors from the bone marrow [217] .
The effect of PRP combined with BMSC was also tested in experimental dental implant models. In a dog mandible model of bone defects, the combination of canine MSC and PRP favoured well-formed mature bone formation and neo-vascularization, comparable with that induced by autologous cancellous bone, whereas PRP alone performed poorly [218] . In other experiments, the combination of MSC-PRP-fibrin gel, used as grafting material for alveolar augmentation in adult dogs, lead to the highest degree of direct bone-implant contact [219] .
From the analysis of the results of in vivo research, it can be concluded that PRP promotes bone healing [220] , particularly in the early phase [221] and in combination with MSC and bone grafts [222, 223] or an artificial scaffold. In the later course of bone healing, the PRP effects were less evident [224, 225] . However, a beneficial effect of PRP on bone healing was not demonstrated in every animal model and with every bone substitute, probably owing to the differences in the protocol design and the method for measuring bone formation [226] .
The clinical use of PRP for bone repair
In orthopaedics, PRP is generally considered a tool for promoting bone repair, even though there have been discordant or inconsistent results [227] . PRP, sometimes combined with MSC, has been proposed for the treatment of non-unions [228] , in femoral and tibial lengthenings [229] , in distraction osteogenesis, in spinal fusions, in foot and ankle surgery and in joint arthroplasties. PRP is also used in odontostomatology and maxillo-facial surgery, to improve bone regeneration.
Non-union
The scientific basis for the use of PRP in non-unions and pseudoarthrosis is the significant reduction of GF which has been observed at the non-union sites, in comparison with the site of fresh fractures [230] . In non-unions, both PRP administration during surgery together with bone allograft and percutaneous administration of PRP have been proposed. PRP with autologous bone graft gave resolution of non-unions of the foot and ankle at a mean of 60 days [230] . With percutaneous administration healing was improved only if the treatment was performed within 11 months after the initial surgery [231] . In a prospective study, PRP, injected into atrophic non-unions, treated with percutaneous stabilization, failed to improve consolidation [232] . Therefore [233] .
Distraction osteogenesis
In distraction osteogenesis of the femur or tibia, for patients with achondroplasia, hypochondroplasia or congenital pseudoarthrosis, PRP in combination with MSC resulted in acceleration of new bone regeneration [234] .
Spinal fusion
In a prospective study on lumbar interbody fusion, PRP with an allogeneic bone graft gave a clinical and radiological outcome at 12 and 24 months comparable to an autologous graft [235] . However, other researchers failed to show an enhancement in lumbar fusion using autologous bone graft with or without PRP [236] .
Foot and ankle surgery
In total ankle arthroplasty PRP improved the syndesmosis union rate [237, 238] . PRP may help to achieve an acceptable time for fusion also in high-risk patients with diabetes, immunosuppression, malnutrition, alcohol abuse, osteomyelitis and history of impaired osseous healing or multiple same site surgeries [239] . [241] . Implants of ␤-TCP seeded with MSC and PRP for maxillary sinus floor augmentation were clinically stable 12 months after loading [242] . Recently, PRP associated with cancellous marrow grafting has been proposed in selected cases of osteonecrosis of the jaws [243] . A systematic review of human controlled clinical trials designed to treat maxillofacial bony defects with the application of PRP found evidence for beneficial effects in the treatment of periodontal defects, but minimal effects in sinus elevation [244] .
Total knee arthroplasty
There [245] . Only one was a randomized controlled study [246] 
Molecular control of osteogenesis
The timeline of molecular events that regulate osteogenesis has been described by Li et al., [250] , the time course and extent of gene expression in in vitro expanded osteogenic precursors is not significantly different from that which has been observed in vivo [251] . The gene expression profile of hMSC undergoing osteogenic induction has been analysed at different time-points until MSC were able to form mineral nodules [252] . As expected, in the early stage of differentiation most of the up-regulated genes are related to cell proliferation, whereas in later stages the expression of genes with a biological function relevant to osteogenesis, such as GF-signalling pathways, bone related genes and adhesion molecules, gradually increases (Fig. 6) . In recent years the most important pathways which are known to play important roles in driving the osteogenic differentiation of MSC have been identified by in vitro and in vivo studies [253] [254] [255] [256] [257] [258] .
TGF-␤ signalling
The TGF-␤ superfamily is a large family of growth and differentiation factors including 34 members at least [259] . BMPs are members of the TGF-␤ superfamily and have a strong impact on osteoprogenitor differentiation, although it has been shown that osteogenesis is initiated normally in BMP-deficient mice [250] [262] . [272, 273] . The binding of Wnt proteins to the FZD/Lrp5/6 complex generates a signal, which inhibits the activity of glycogen synthase kinase 3 (GSK-3). GSK-3 inactivity blocks the phosphorylation of ␤-catenin, and prevents its degradation in the cytoplasm by the ubiquitin-pathway, leading to translocation of ␤-catenin into the nucleus where it cooperates with transcription factors of the T-cell factor/lymphoid enhancer factor family [274] . The ␤-catenin activity seems to be a requirement to direct the bipotential osteochondroprogenitor towards a specific lineage. Indeed, the ␤-catenin/T-cell factor 1 complex enhances expression and activity of the osteogenic promoter Runx2, whereas low levels of ␤-catenin direct the mesenchymal precursors toward chondrogenesis [275] . [283] . The reverse signalling from EphB4 in osteoblasts to ephrinB2 in osteoclast progenitors leads to the inhibition of osteoclast differentiation, whereas the forward signalling through EphB4 induces osteogenic transcription factors [284] . However, ephrinA2-EphA2 interaction facilitates the initiation phase of bone remodelling by enhancing osteoclast differentiation and suppressing osteoblast differentiation [285] .
Fig. 6 Schematic representation of the principal signalling networks and transcription factors regulating osteoblast differentiation and osteogenesis (see text for details). Lines with arrowheads indicate a positive action, lines with bars indicate an inhibition and dashed lines indicate that function has to
Hedgehog signalling
Transcription factors regulating osteoblast differentiation
The signalling pathways described above lead to the activation of transcription factors that exert positive and negative regulatory effects on the expression of genes controlling the acquisition of the osteoblast phenotype [255, 286] [289] .
Conclusion
The 
